Inozyme Pharma, Inc. Quarterly Liabilities in USD from Q4 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
Summary
Inozyme Pharma, Inc. quarterly Liabilities history and growth rate from Q4 2019 to Q3 2024.
  • Inozyme Pharma, Inc. Liabilities for the quarter ending September 30, 2024 was $60.6M, a 33.2% increase year-over-year.
Liabilities, Quarterly (USD)
Liabilities, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $60.6M +$15.1M +33.2% Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $61.3M +$16M +35.2% Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $58.1M +$19.7M +51.1% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $60.4M +$39.6M +190% Dec 31, 2023 10-Q 2024-11-05
Q3 2023 $45.5M +$26.2M +136% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $45.3M +$32.5M +254% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $38.4M +$23.7M +162% Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $20.8M +$6.53M +45.7% Dec 31, 2022 10-K 2024-03-12
Q3 2022 $19.2M +$7.47M +63.4% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $12.8M +$2.83M +28.3% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $14.7M +$4.68M +46.6% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $14.3M +$3.01M +26.8% Dec 31, 2021 10-K 2023-03-22
Q3 2021 $11.8M +$695K +6.27% Sep 30, 2021 10-Q 2021-11-09
Q2 2021 $9.99M +$3.02M +43.4% Jun 30, 2021 10-Q 2021-08-11
Q1 2021 $10M Mar 31, 2021 10-Q 2021-05-12
Q4 2020 $11.3M +$8.02M +248% Dec 31, 2020 10-K 2022-03-15
Q3 2020 $11.1M Sep 30, 2020 10-Q 2020-11-12
Q2 2020 $6.97M Jun 30, 2020 10-Q 2020-09-03
Q4 2019 $3.24M Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.